Highlights

  • Invion (ASX:IVX) is developing the Photosoft photodynamic therapy platform for medical applications.
  • The company is exploring Photosoft in wet age-related macular degeneration research.
  • INV043 remains a key clinical programme focused on non-melanoma skin cancer.
  • Funding capacity and clinical progress remain important factors for future development.

Invion Limited (ASX:IVX) is an Australian clinical-stage biotechnology company focused on developing the Photosoft platform, a photodynamic therapy technology that combines a light-activated drug with specific wavelengths of light. The company is exploring applications across disease areas, with current development activities including non-melanoma skin cancer and research into eye disease.

How the Photosoft Platform Works

Invion describes Photosoft as a technology that combines therapeutic and diagnostic capabilities. The platform uses a drug activated by light to target diseased tissue, while another wavelength can provide visual identification of treated areas.

The company is investigating whether this approach can provide a different method of identifying and treating abnormal tissue. Clinical validation remains an important step in determining the broader application of the technology.

Skin Cancer Programme Remains Central

Invion’s INV043 programme is focused on non-melanoma skin cancer. During 2026, the company progressed the study into additional patient groups following review by an independent safety committee.

The company has reported early clinical observations from the programme, including lesion-size reductions and responses in treated patients. These findings remain from early-stage clinical development and require further evaluation as the programme progresses.

Exploring Eye Disease Applications

Invion has expanded research activities into wet age-related macular degeneration (wet AMD), a condition associated with vision loss. The company entered a research Partnership to explore Photosoft applications in this area.

The eye disease programme is currently at an early research stage rather than a commercial product phase. Further studies would be required to determine whether Photosoft can be applied effectively in ophthalmology.

Funding and Development Considerations

As a clinical-stage biotechnology company, Invion requires ongoing resources to support research programmes, clinical studies and regulatory activities. The company reported a limited cash position at 30 June 2026 and has highlighted disciplined spending and research-related funding support.

Future progress will depend on advancing clinical programmes, developing partnerships and maintaining the financial resources required to continue research activities.

Key Insights

Invion is attempting to expand the application of Photosoft beyond its initial development areas by exploring additional medical uses. The company’s progress will depend on generating further clinical evidence, advancing regulatory pathways and managing the requirements of biotechnology development.